Johnson & Johnson and Legend Biotech are investing in expanding their mega-production site for blood cancer therapy in Ghent to keep up with demand. It concerns an amount of 150 million dollars (138 million euros).
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Johnson & Johnson and Legend Biotech are investing in expanding their mega-production site for blood cancer therapy in Ghent to keep up with demand. It concerns an amount of 150 million dollars (138 million euros).